Pancreatic Cancer Research

ResearcherRice UniversityActive in the last 2 years

Maciej Serda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4926-5782; OpenAlex author ID A5018472646. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
6
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 3

  1. Aminofullerenes as targeted inhibitors of EGFR: from pancreatic cancer inhibitors to Drosophila m. Toxicology. Last author DOI 10.1080/17435889.2025.2461985↗
  2. Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment. Co-author DOI 10.1038/s41598-019-57155-7↗
  3. Development of photoactive Sweet-C60 for pancreatic cancer stellate cell therapy. Co-author DOI 10.2217/nnm-2018-0239↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Katarzyna Malarz · 2 shared papers, 2020–2025 · strength 0.35
  2. Tao Sun · 1 shared paper, 2025 · strength 0.22
  3. Steven A. Curley · 2 shared papers, 2018–2020 · strength 0.21
  4. Matthew J. Ware · 1 shared paper, 2018 · strength 0.08
  5. Stuart J. Corr · 1 shared paper, 2018 · strength 0.08
  6. Martyna Krzykawska-Serda · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.